BIOMILQ
Unlocking human potential with breakthrough mammary biotechnology.
Unlocking human potential with breakthrough mammary biotechnology.
BIOMILQ is a groundbreaking mammary biotechnology startup that aims to bridge the gap between breast milk and infant formula. Founded in 2020 and headquartered in the United States, it is women-owned and science-led, leveraging patented technology to produce functional cell-cultured human milk components outside the body. The company's mission is to revolutionize early-life nutrition by bringing more of the benefits of breast milk to more babies. Their last investment of $21.00M in a Series A round occurred on 20th October 2021, with participation from notable investors including Blue Horizon, Gaingels, Novo Holdings, Spero Ventures, Breakthrough Energy Ventures, Digitalis Ventures, Green Generation Fund, and Alexandria. Operating at the intersection of Biotechnology and Food and Beverage industries, BIOMILQ is poised to make a significant impact on the future of infant nutrition.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $21.00M | 8 |
|
20 Oct 2021 |
| Seed Round | $3.50M | 2 |
|
16 Jun 2020 |
| Seed Round | Unknown | - | 05 Jan 2020 |
No recent news or press coverage available for BIOMILQ.
We care about your data, and we'd love to use cookies make your experience better.
-logo.){kind=logo}